Assyro Team
20 min read
eCTD Module 5: Clinical Study Reports and Data Organization Guide
Quick Answer
eCTD Module 5 contains the clinical study reports and related clinical data from the development program. It is organized per ICH M4E(R2) into a tabular listing of studies (5.2), clinical study reports categorized by type (5.3), and literature references (5.4). Individual clinical study reports follow the ICH E3 format.
Key Takeaways
Key Takeaways
- Module 5 organizes clinical information per ICH M4E(R2) into biopharmaceutic, PK, PD, efficacy/safety, post-marketing, and case-report-form or listing categories.
- Section 5.2 should provide a complete and transparent tabular listing of the relevant clinical studies, including unfavorable or failed studies where they bear on the application.
- For applicable submissions that must use standardized electronic study data under section 745A(a), sponsors should follow FDA's current Study Data Standards Resources and Data Standards Catalog.
- Individual clinical study reports must follow the ICH E3 format, and data consistency between Module 5 reports and Module 2 summaries must be verified through rigorous QC.
- eCTD Module 5 is the clinical evidence module of the Common Technical Document. It contains the clinical study reports and supporting clinical data from the development program, organized by study type and purpose. This module provides the underlying evidence that supports the safety and efficacy conclusions presented in Module 2 (Sections 2.5 and 2.7).
- For FDA reviewers, Module 5 is where they go to independently verify the sponsor's claims. Medical officers, statistical reviewers, and clinical pharmacology reviewers each focus on specific sections of Module 5 relevant to their discipline. The organization and completeness of Module 5 directly affects review efficiency and the likelihood of Information Requests during review.
- In this guide, you will learn:
- The complete Module 5 structure per ICH M4E(R2)
- How clinical studies are categorized and placed within Module 5
- The ICH E3 clinical study report format
- Tabular listing requirements for all clinical studies
- Individual patient data and listings requirements
- Literature reference handling
- Cross-referencing between Module 5 and Module 2 (Sections 2.5 and 2.7)
- ---
Module 5 Structure Overview
Complete Organization per ICH M4E(R2)
| Section | Title | Content |
|---|---|---|
| 5.1 | Table of Contents | Module 5 document listing |
| 5.2 | Tabular Listing of All Clinical Studies | Summary table of every clinical study |
| 5.3 | Clinical Study Reports | All individual study reports organized by category |
| 5.4 | Literature References | Published literature supporting the application |
Section 5.3 Detailed Structure
The clinical study reports in Section 5.3 are organized into sub-categories that correspond to different types of clinical investigations:
| Section | Category | Study Types |
|---|---|---|
| 5.3.1 | Biopharmaceutic Studies | BA, BE, in vitro dissolution, food effect |
| 5.3.2 | Studies Pertinent to Pharmacokinetics Using Human Biomaterials | In vitro protein binding, metabolism, CYP studies |
| 5.3.3 | Reports of Human PK Studies | PK, DDI, special population PK, population PK |
| 5.3.4 | Reports of Human Pharmacodynamic (PD) Studies | PD studies, dose-response, PD drug interaction |
| 5.3.5 | Reports of Efficacy and Safety Studies | Pivotal and supportive controlled studies |
| 5.3.6 | Reports of Post-Marketing Experience | Post-marketing surveillance data |
| 5.3.7 | Case Report Forms and Individual Patient Listings | Individual patient data |
Section 5.2: Tabular Listing of All Clinical Studies
Purpose
Section 5.2 provides a single, comprehensive table listing the clinical studies relevant to the development program. This table gives reviewers an immediate overview of the clinical evidence package and its organization within the application.
Required Table Format
| Column | Content | Notes |
|---|---|---|
| Study Number | Unique study identifier | Sponsor's internal numbering |
| Study Title | Descriptive title | Including phase, design, population |
| Study Type | Phase 1/2/3/4, PK, BA/BE, etc. | Per Section 5.3 categorization |
| Study Design | Randomized, controlled, blind, etc. | Key design features |
| Study Population | Healthy volunteers, patients, special pop | Demographics summary |
| Number of Subjects | Enrolled / completed | Total and per treatment group |
| Dose/Regimen | Drug name, dose, route, frequency | Including comparator |
| Duration | Treatment and follow-up | Total exposure period |
| Study Status | Completed, ongoing, terminated | Current status |
| Location in eCTD | Section 5.3.X.X reference | Where the full report is placed |
What to Include
All studies must be listed, including:
- Completed studies (whether positive, negative, or equivocal)
- Ongoing studies (with available interim data if relevant)
- Terminated studies (with reason for termination)
- Studies conducted by other sponsors (if referenced under license or right of reference)
- Published literature studies (cross-referenced to Section 5.4)
“Transparency Requirement: Section 5.2 should present a complete and transparent tabular listing of the studies being relied on and the broader development record, including studies with unfavorable findings where relevant to the application.
Section 5.3.1: Biopharmaceutic Studies
Scope
Section 5.3.1 contains reports of biopharmaceutic studies that characterize the drug product's in vivo performance.
| Sub-Section | Study Type | Typical Studies |
|---|---|---|
| 5.3.1.1 | Bioavailability (BA) Study Reports | Absolute and relative bioavailability |
| 5.3.1.2 | Comparative BA and Bioequivalence (BE) Study Reports | Formulation bridging, food effect, proportionality |
| 5.3.1.3 | In Vitro - In Vivo Correlation (IVIVC) Study Reports | Dissolution-PK correlation models |
| 5.3.1.4 | Reports of Bioanalytical and Analytical Methods | Bioanalytical method validation reports for BA/BE studies |
Key Considerations
- Formulation bridging: If the commercial formulation differs from the clinical trial formulation used in pivotal studies, a BA/BE bridging study is required to demonstrate comparable exposure
- Food effect: FDA Guidance, "Food-Effect Bioavailability and Fed Bioequivalence Studies" (December 2002), outlines when food effect studies are needed
- Bioanalytical validation: All bioanalytical methods must be validated per FDA Guidance, "Bioanalytical Method Validation" (May 2018), covering accuracy, precision, selectivity, sensitivity, reproducibility, and stability
Section 5.3.2: Studies Pertinent to Pharmacokinetics Using Human Biomaterials
Scope
This section contains in vitro studies using human biological materials (e.g., microsomes, hepatocytes, recombinant enzymes, plasma) that inform the pharmacokinetic profile.
| Study Type | Purpose |
|---|---|
| Plasma protein binding | Fraction bound, displacement potential |
| Hepatocyte metabolism | Metabolic stability, metabolite identification |
| CYP inhibition | IC50/Ki for major CYP enzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4) |
| CYP induction | Induction potential using human hepatocytes |
| Transporter studies | P-gp, BCRP, OATP, OCT, OAT, MATE substrate/inhibitor assessment |
| CYP phenotyping | Identification of enzymes responsible for metabolism |
These studies inform the clinical drug interaction strategy and the labeling recommendations for drug interactions.
“FDA Guidance Reference: "In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions" (January 2020) provides the definitive framework for these studies.
Section 5.3.3: Reports of Human PK Studies
Scope
Section 5.3.3 contains human pharmacokinetic study reports, including PK characterization, drug interaction studies, and special population PK studies.
| Sub-Section | Study Type | Content |
|---|---|---|
| 5.3.3.1 | Healthy Subject PK and Initial Tolerability | First-in-human, SAD, MAD, PK characterization |
| 5.3.3.2 | Patient PK and Initial Tolerability | PK in target population |
| 5.3.3.3 | Intrinsic Factor PK Studies | Hepatic impairment, renal impairment, age, sex, race, body weight, genetic polymorphism |
| 5.3.3.4 | Extrinsic Factor PK Studies | Drug-drug interaction studies, food effect (clinical PK) |
| 5.3.3.5 | Population PK Studies | Population PK analysis reports, covariate analyses |
Intrinsic Factor Studies (5.3.3.3)
FDA expects dedicated studies or population PK assessments for intrinsic factors:
| Factor | Study Type | FDA Guidance |
|---|---|---|
| Hepatic impairment | Dedicated study (Child-Pugh A/B/C) | "Pharmacokinetics in Patients with Impaired Hepatic Function," May 2003 |
| Renal impairment | Dedicated study (mild/moderate/severe/ESRD) | "Pharmacokinetics in Patients with Impaired Renal Function," September 2020 |
| Age (elderly) | Population PK or dedicated | ICH E7 |
| Pediatric PK | Pediatric PK studies or extrapolation | ICH E11(R1), PREA |
| Genetic polymorphism | Pharmacogenomic analysis | FDA Guidance on Pharmacogenomics |
Drug-Drug Interaction Studies (5.3.3.4)
Clinical DDI studies are typically required based on in vitro results (Section 5.3.2):
| Study Type | When Required | Design |
|---|---|---|
| CYP3A4 inhibitor effect | Drug is CYP3A4 substrate | Study with strong inhibitor (e.g., itraconazole) |
| CYP3A4 inducer effect | Drug is CYP3A4 substrate | Study with strong inducer (e.g., rifampin) |
| Drug as inhibitor | In vitro CYP inhibition | Study with sensitive substrate |
| Drug as inducer | In vitro CYP induction | Study with sensitive substrate |
| Transporter-based DDI | Drug is transporter substrate/inhibitor | Study with appropriate probe |
“FDA Guidance Reference: "Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions" (January 2020)
Section 5.3.4: Reports of Human Pharmacodynamic (PD) Studies
Scope
Section 5.3.4 contains clinical pharmacodynamic study reports, including dose-response studies in patients and pharmacodynamic drug interaction studies. These studies characterize the drug's pharmacological effect in humans and inform dose selection.
| Sub-Section | Content | |
|---|---|---|
| 5.3.4.1 | Reports of PD and Dose-Response Studies | Dose-response, PD endpoint studies |
| 5.3.4.2 | Reports of PD Drug Interaction Studies | Clinical PD interaction assessments |
Section 5.3.5: Reports of Efficacy and Safety Studies
Scope
Section 5.3.5 contains the pivotal (primary evidence) clinical study reports, along with their associated analyses.
| Sub-Section | Content | |
|---|---|---|
| 5.3.5.1 | Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication | Pivotal efficacy studies - the primary evidence for approval |
| 5.3.5.2 | Study Reports of Uncontrolled Clinical Studies | Supportive uncontrolled studies |
| 5.3.5.3 | Reports of Analyses of Data from More Than One Study | Integrated summaries of safety (ISS), integrated summaries of efficacy (ISE), pooled analyses, meta-analyses |
| 5.3.5.4 | Other Study Reports | Studies not fitting other categories |
Section 5.3.5.1: Pivotal Studies
This is the single most important section in Module 5. It contains the full clinical study reports for the adequate and well-controlled studies (per 21 CFR 314.126) that provide the primary evidence of effectiveness.
Each pivotal study report should follow the ICH E3 format (see below) and include:
- Complete study report with all appendices
- Statistical analysis plan (SAP) as a separate document
- Protocol and all amendments
- Informed consent form (sample)
- IRB/Ethics committee approvals list
- Randomization code
- Patient data listings
Section 5.3.5.3: Integrated Analyses
This section contains analyses that combine data across multiple studies:
| Analysis Type | Purpose | FDA Expectation |
|---|---|---|
| Integrated Summary of Safety (ISS) | Pool all safety data across studies | Expected for most NDAs (see FDA Guidance) |
| Integrated Summary of Efficacy (ISE) | Pool efficacy data from pivotal studies | May be required for complex programs |
| Pooled analysis | Pre-specified analysis combining trial data | Per statistical analysis plan |
| Meta-analysis | Formal meta-analysis across trials | If applicable, following PRISMA |
Section 5.3.6: Reports of Post-Marketing Experience
This section is typically empty for original NDAs/BLAs (since the product has not yet been marketed). It is populated for:
- Supplemental applications (new indications for marketed products)
- Products with foreign marketing experience
- Products previously approved under a different sponsor
Content includes:
- Post-marketing safety reports
- Adverse event reports from marketed use
- Safety signal assessments
- Post-marketing study results
Section 5.3.7: Case Report Forms and Individual Patient Listings
Scope
Section 5.3.7 contains individual patient-level data, including case report forms (CRFs) and patient data listings.
| Content Type | What Is Included |
|---|---|
| Case report forms | Individual CRFs for patients who died, discontinued due to AEs, or had serious adverse events (at minimum) |
| Patient listings | Line listings of all patients by treatment group, demographics, disposition, efficacy response, adverse events |
| Individual patient narratives | Detailed narratives for patients with notable outcomes (deaths, SAEs, treatment failures) |
| Datasets | Analysis-ready datasets (CDISC SDTM and ADaM formats) |
CDISC Requirements
FDA requires submission of clinical study data in CDISC (Clinical Data Interchange Standards Consortium) format:
| Standard | Purpose | Requirement |
|---|---|---|
| SDTM (Study Data Tabulation Model) | Tabulation datasets | Follow FDA's current study data standards requirements where applicable |
| ADaM (Analysis Data Model) | Analysis-ready datasets | Follow FDA's current study data standards requirements where applicable |
| Define.xml | Data definition file | Expected for standardized electronic study data submissions |
| Reviewer's Guide | Navigation document | Used to help reviewers understand the submitted datasets |
| ADRG (Analysis Data Reviewer's Guide) | Analysis methodology | Used where applicable to explain submitted analysis datasets |
“FDA Data Standards Point: FDA's requirements for electronic study data are governed by section 745A(a) and the agency's current study data standards resources. Sponsors should verify the currently supported standards and implementation expectations at the time of submission.
ICH E3: Clinical Study Report Format
Overview
ICH E3, "Structure and Content of Clinical Study Reports," defines the standardized format for clinical study reports included in Module 5. Every complete study report in Module 5 should follow this structure.
ICH E3 Report Structure
| Section | Title | Content |
|---|---|---|
| Section 1 | Title Page | Study number, title, sponsor, investigator, phase, dates |
| Section 2 | Synopsis | 2-3 page study summary (standard format) |
| Section 3 | Table of Contents | Complete report TOC |
| Section 4 | List of Abbreviations | All abbreviations used |
| Section 5 | Ethics | IRB/EC approvals, informed consent, regulatory compliance |
| Section 6 | Investigators and Study Administrative Structure | List of all investigators and sites |
| Section 7 | Introduction | Background, rationale |
| Section 8 | Study Objectives | Primary and secondary objectives |
| Section 9 | Investigational Plan | Study design, population, treatments, endpoints, statistics |
| Section 10 | Study Patients | Disposition, protocol deviations, demographics |
| Section 11 | Efficacy Evaluation | Primary and secondary endpoint results, subgroup analyses |
| Section 12 | Safety Evaluation | AEs, deaths, SAEs, labs, vital signs, ECG |
| Section 13 | Discussion and Overall Conclusions | Interpretation, benefit-risk |
| Section 14 | Tables, Figures, and Graphs | All referenced tables and figures |
| Section 15 | Reference List | Literature references |
| Section 16 | Appendices | Protocol, SAP, CRFs, patient listings, datasets |
Synopsis Format
The study synopsis in ICH E3 follows a fixed format that should be consistent across all Module 5 studies:
| Element | Content |
|---|---|
| Study number | Sponsor's study identifier |
| Title | Full descriptive title |
| Coordinating investigator | Name and institution |
| Study centers | Number and location |
| Publication reference | If applicable |
| Study period | First patient in to last patient out |
| Phase | Phase 1, 2, 3, or 4 |
| Objectives | Primary and secondary |
| Methodology | Design, randomization, blinding |
| Number of subjects | Planned and actual (enrolled, randomized, completed, analyzed) |
| Diagnosis and criteria | Key inclusion/exclusion criteria |
| Test product, dose, mode of administration | Drug, formulation, dose, route, frequency |
| Duration of treatment | Per protocol |
| Reference therapy | Comparator, dose, route |
| Criteria for evaluation | Primary and secondary endpoints |
| Statistical methods | Primary analysis, sample size justification |
| Summary of results - efficacy | Primary endpoint results, p-values, confidence intervals |
| Summary of results - safety | AE summary, SAEs, discontinuations |
| Conclusions | Study conclusions |
| Date of report | Report completion date |
“Best Practice: The synopsis should be written so that it can be read independently as a standalone document. It serves as the basis for Module 2 Section 2.7.6 (Individual Study Synopses).
Section 5.4: Literature References
Scope
Section 5.4 contains copies of published literature cited in the clinical sections of the application. This includes:
| Type | Examples |
|---|---|
| Efficacy literature | Published clinical trial results for the drug or drug class |
| Safety literature | Published case reports, safety analyses |
| Pharmacokinetic literature | Published PK data for the drug or related compounds |
| Epidemiological studies | Disease prevalence, natural history data |
| Methodological references | Validated endpoints, statistical methods |
Requirements
- Full copies of all cited articles (not just abstracts)
- Organized with clear cross-references to where each is cited in the application
- For 505(b)(2) applications, published literature may serve as a key evidence source per FDA Guidance on 505(b)(2) applications
Cross-Referencing Module 5 to Module 2
Module 5 study reports provide the source data for two Module 2 sections:
| Module 2 Section | Relationship to Module 5 | Cross-Reference Method |
|---|---|---|
| 2.5 Clinical Overview | Interprets Module 5 data across studies; provides benefit-risk assessment | Reference study by study number and Module 5 section (e.g., "Study XYZ-301 (Module 5.3.5.1)") |
| 2.7 Clinical Summary | Summarizes Module 5 data by category (biopharmaceutics, clinical PK, efficacy, safety) | Each sub-section of 2.7 draws from corresponding Module 5 sections |
Consistency Requirements
Critical data points that must be consistent between Module 5 and Module 2:
| Data Element | Module 5 Source | Module 2 Destination |
|---|---|---|
| Number of subjects randomized | Study report Section 10 | 2.7.3 (efficacy), 2.7.4 (safety) |
| Primary endpoint results | Study report Section 11 | 2.5.4 (efficacy overview), 2.7.3 |
| AE incidence rates | Study report Section 12 | 2.5.5 (safety overview), 2.7.4 |
| Deaths and SAEs | Study report Section 12 | 2.5.5, 2.7.4, 2.7.6 |
| PK parameters | Study report results | 2.5.3, 2.7.1, 2.7.2 |
| Study conclusions | Study report Section 13 | 2.5.6 (benefit-risk), 2.7.6 |
“Common Error: Discrepancies between Module 5 reports and the corresponding Module 2 summaries can create significant review questions. A rigorous quality-control process comparing numerical values across modules is essential.
Module 5 Practical Considerations
eCTD Publishing Considerations
- PDF specifications: Each study report is published as a set of PDFs per FDA eCTD technical specifications (bookmarks, hyperlinks, pagination requirements)
- Granularity: Follow FDA/ICH guidance on document granularity (how to split large reports into manageable PDF files)
- Datasets: CDISC datasets are included as SAS transport files (xpt format) alongside the study report PDFs
- Validation: Run eCTD validation prior to submission to verify Module 5 structure, file naming, and XML backbone integrity
Common Module 5 Review Issues
| Deficiency | Impact | Prevention |
|---|---|---|
| Missing study reports for listed studies | Information Request; potential RTF | Cross-check 5.2 table against 5.3 contents |
| Non-CDISC datasets | Refuse to File risk | Submit in SDTM/ADaM format per FDA Data Standards Catalog |
| Incomplete ICH E3 reports | Review delay | Use ICH E3 checklist for each study report |
| Missing patient narratives for deaths/SAEs | Safety review delay | Prepare narratives for all deaths, SAEs, and AE-related discontinuations |
| Inconsistent data between studies and summaries | Information Request | QC reconciliation between Module 5 and Module 2 |
| Missing statistical analysis plan | Cannot verify pre-specification | Include final SAP as appendix to each pivotal study report |
| Inadequate study synopses | Module 2.7.6 gaps | Ensure every study has a complete ICH E3 synopsis |
The number of studies varies widely by product, indication, and development strategy. What matters for review is that the studies are organized correctly, listed transparently, and supported by the required reports, datasets, and appendices.
Key Regulatory References
| Reference | Citation |
|---|---|
| ICH M4E(R2) | Efficacy - Clinical Overview and Clinical Summary |
| ICH E3 | Structure and Content of Clinical Study Reports |
| ICH E6(R2) | Good Clinical Practice |
| ICH E9(R1) | Statistical Principles for Clinical Trials |
| ICH E1 | Population Exposure for Long-Term Treatment |
| ICH E7 | Studies in Support of Special Populations: Geriatrics |
| ICH E11(R1) | Clinical Investigation of Medicinal Products in the Paediatric Population |
| NDA Content Requirements | 21 CFR 314.50 |
| Adequate and Well-Controlled Studies | 21 CFR 314.126 |
| FDA Study Data Standards Resources | FDA, current version |
| FDA Data Standards Catalog | FDA, current version |
| FDA Bioanalytical Method Validation | FDA Guidance, May 2018 |
| FDA Clinical DDI Guidance | FDA, January 2020 |
| FDA In Vitro DDI Guidance | FDA, January 2020 |
| FDA Renal Impairment Guidance | FDA, September 2020 |
| FDA Food-Effect BA Guidance | FDA, December 2002 |